Related Experiment Videos
[UFT-E granule compliance in postoperative adjuvant chemotherapy].
H Komoriyama1, A Hanai, K Kanasugi
1Division of Surgery, St. Marianna University Yokohama City Seibu Hospital.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|September 9, 1999
Summary
UFT-E granules show feasible long-term use in adjuvant chemotherapy for gastric, colorectal, and breast cancer patients, with mild side effects and high compliance rates observed in this study.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Context:
- Adjuvant chemotherapy plays a crucial role in managing resected gastrointestinal and breast cancers.
- Optimizing drug delivery and patient adherence is essential for effective long-term cancer treatment.
- UFT-E granules represent a potential oral chemotherapeutic agent for postoperative adjuvant therapy.
Purpose:
- To evaluate the feasibility, dose conditions, and safety of long-term (one year) postoperative adjuvant chemotherapy using UFT-E granules.
- To assess patient compliance and identify factors influencing adherence to UFT-E granule treatment.
- To investigate the clinical laboratory test abnormalities and complications associated with UFT-E granule administration.
Summary:
- This study involved 19 patients (5 gastric, 10 colorectal, 7 breast cancer) receiving UFT-E granules post-surgery.
- The mean administration period was 459 days with a 92.5% completion rate and a mean dose rate of 86.3%.
- Complications were mild in 21.1% of cases, suggesting UFT-E granules are feasible for long-term use with acceptable tolerability.
Impact:
- Findings support the long-term administration of UFT-E granules as a viable adjuvant chemotherapy option with manageable side effects.
- Emphasizes the need for detailed monitoring of dose conditions to ensure high patient compliance.
- Contributes to understanding the clinical utility of oral UFT-E granules in adjuvant cancer therapy.